Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impact of Treatment With Trifluridine/Tipiracil in Combination With Bevacizumab on Health-Related Quality of Life and Performance Status in Refractory Metastatic Colorectal Cancer: An Analysis of the Phase III SUNLIGHT Trial.
Clin Colorectal Cancer
December 2024
Medical University Vienna, Department of Medicine I, Vienna, Austria. Electronic address:
Background: The efficacy of trifluridine/tipiracil (FTD/TPI) + bevacizumab compared to FTD/TPI for treatment of refractory metastatic colorectal cancer (mCRC) was demonstrated in the SUNLIGHT trial. This analysis of SUNLIGHT investigated the impact of treatment with FTD/TPI + bevacizumab on patient quality of life (QoL) and Eastern Cooperative Oncology Group performance status (ECOG PS).
Methods: Questionnaires (EORTC QLQ-C30 and EQ-5D-5L) and ECOG PS assessments were conducted at baseline and on Day 1 of each treatment cycle.
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.
Lancet Diabetes Endocrinol
January 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Electronic address:
Background: Data on the effect of mineralocorticoid receptor antagonist therapy on HbA levels and new-onset diabetes are conflicting. We aimed to examine the effect of oral finerenone, compared with placebo, on incident diabetes in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) trial.
Methods: In this randomised, double-blind, placebo-controlled trial, 6001 participants with heart failure with New York Heart Association functional class II-IV, left ventricular ejection fraction 40% or higher, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomly assigned to finerenone or placebo, administered orally.
Development, content validation and feasibility of a decision aid tool for the treatment of women with menopausal symptoms.
Maturitas
January 2025
Theramex, London, UK. Electronic address:
Introduction: Despite research supporting menopause hormonal therapy for menopausal women, its use continues to decline in most European countries and the United States. Experts highlighted the need for global assessment tools to assist clinicians in evaluating treatment for symptomatic menopausal women, which led to the development of the Menopause Treatment Tool, with separate versions for women and healthcare professionals. Both versions of the tool focus on menopausal symptoms, risk levels and suggested actions; the women's tool is administered prior to the consultation, while the clinician tool is administered by the clinician during the clinical consultation.
View Article and Find Full Text PDFReply to Editorial Comment on "A Global Survey to Assess Urologists' Attitudes Towards Suction Technology in Endourology by the European Association of Urology Section of Endourology and Progressive Endourological Association for Research and Leading Solutions".
Urology
January 2025
European Association of Urology Section of Endourology, Arnhem, the Netherlands; Department of Urology, Ng Teng Fong Hospital, Singapore, Singapore.
A glucocorticoid-free era for polymyalgia rheumatica: are we on the brink of change?
Lancet Rheumatol
January 2025
Department of Rheumatology, Hospital of Brunico, Teaching Hospital of the Paracelsius Medical University, Brunico 39031, Italy; Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Medical University, Graz, Austria. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!